Trial Profile

A Multicenter, Open-Label Extension Study to Asses the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants With Active Axial Spondyloarthritis, Ankylosing Spondylitis, and Nonradiographic Axial Spondyloarthritis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 16 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bimekizumab (Primary)
Indications Ankylosing spondylitis; Axial spondyloarthritis; Non-radiographic axial spondyloarthritis
Focus Adverse reactions; Registrational
Acronyms BE MOVING
Sponsors UCB Biopharma

11 Jun 2025 Results presented in the UCB pharmaceutical Media Release.
11 Jun 2025 According to a UCB pharmaceutical media release, company will present data from this study at EULAR 2025 in Barcelona, Spain, 11-14 June.
15 Jun 2024 Results evaluating impact of BKZ treatment on 2-year radiographic progression in the spine of patients with r-axSpA , presented at the 25th Annual Congress of the European League Against Rheumatism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com